Vext Science ( (VEXTF) ) has released its Q1 earnings. Here is a breakdown of the information Vext Science presented to its investors.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Vext Science, Inc. is a U.S.-based cannabis operator with vertical operations in Arizona and Ohio, specializing in cultivation, manufacturing, and retail of cannabis products, including the Vapen brand of THC concentrates and edibles.
In its latest earnings report, Vext Science announced a record performance for the first quarter of 2025, with revenue reaching $11.6 million, marking a 38% increase from the same period last year. The company also achieved $3.1 million in operating cash flow, matching its entire cash generation for the previous year.
Key financial highlights include a significant rise in adjusted EBITDA to $3.36 million, up from $1.96 million in Q1 2024, and a 29% adjusted EBITDA margin. The company’s strategic expansion in Ohio, including the acquisition of additional dispensaries, has contributed to its robust revenue growth. Additionally, Vext has entered into an agreement to sell a medical cannabis processing license in Kentucky, further optimizing its operations.
Looking ahead, Vext Science remains focused on expanding its footprint in Ohio and enhancing its retail strategy to deliver sustainable returns for shareholders. The company aims to leverage its strong capital structure and operating cash flow to continue building equity value through 2025.